×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
|
Dashboard
Analyses
Exchange
Gaps
←
Home
/
Wiki
/
Clinical: A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-C
clinical
2,483 words
KG: ent-clin-3eeade26
Contents
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study t... (NCT05348785)
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Related Hypotheses (30)
Purinergic Signaling Polarization Control
Score: 0.71
Mechanosensitive Ion Channel Reprogramming
Score: 0.70
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.67
Optogenetic Control of Mitochondrial Transfer Networks
Score: 0.48
Senescent Microglia Resolution via Maresins-Senolytics Combi
Score: 0.78
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.76
Senescent Cell Mitochondrial DNA Release
Score: 0.74
Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.74
SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK
Score: 0.74
Phase-Separated Organelle Targeting
Score: 0.73
TFAM overexpression creates mitochondrial donor-recipient gr
Score: 0.73
Stress Granule Phase Separation Modulators
Score: 0.72
Orexin-Microglia Modulation Therapy
Score: 0.71
Lysosomal Enzyme Trafficking Correction
Score: 0.71
Microglial Efferocytosis Enhancement via GPR32 Superagonists
Score: 0.70
Lysosomal Calcium Channel Modulation Therapy
Score: 0.70
Mitochondrial Transfer Pathway Enhancement
Score: 0.70
Lysosomal Positioning Dynamics Modulation
Score: 0.69
CX43 hemichannel engineering enables size-selective mitochon
Score: 0.69
RAB27A-dependent extracellular vesicle engineering for mitoc
Score: 0.67
Metabolic Reprogramming via Microglial Glycolysis Inhibition
Score: 0.67
Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.67
GAP43-mediated tunneling nanotube stabilization enhances neu
Score: 0.67
Biorhythmic Interference via Controlled Sleep Oscillations
Score: 0.66
Mitochondrial RNA Granule Rescue Pathway
Score: 0.66
Mitochondrial SPM Synthesis Platform Engineering
Score: 0.65
Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m
Score: 0.62
Extracellular Vesicle Biogenesis Modulation
Score: 0.56
Lysosomal Membrane Repair Enhancement
Score: 0.54
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.51
Show 25 more
Related Analyses (6)
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
Mitochondrial transfer between neurons and glia
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Show 1 more
Related Experiments (3)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne
validation · proposed · Score: 0.40
See Also (15)
A 6-month & 18-month Prospective, Randomized, Placebo-c
clinical · Pages share 4 hypotheses
Section 253: Advanced Optogenetics and Chemogenetics fo
therapeutic · Pages share 4 hypotheses
A Phase III, Randomized, Double-Blind, Placebo-Controll
clinical · Pages share 4 hypotheses
A Phase 2 Double-Blind, Randomized, Placebo-Controlled
clinical · Pages share 4 hypotheses
Mitochondrial Replacement Therapy for Neurodegeneration
therapeutic · Pages share 4 hypotheses
Section 204: Advanced Proteostasis and Protein Quality
therapeutic · Pages share 4 hypotheses
Optogenetically-Modified Neurons in Neurodegeneration R
cell · Pages share 4 hypotheses
A Phase IIB, Randomized, Double-Blind, Placebo-Controll
clinical · Pages share 4 hypotheses
A Multicenter, Phase III, Randomized, Double Blind, Pla
clinical · Pages share 4 hypotheses
Synaptic Therapy Alzheimer's Research Trial (START): A
clinical · Pages share 4 hypotheses
Neurodegeneration
disease · Pages share 4 hypotheses
Mitochondrial Biogenesis Inducers in Neurodegeneration
therapeutic · Pages share 4 hypotheses
Section 194: Advanced Mitochondrial Dynamics and Biogen
therapeutic · Pages share 4 hypotheses
Section 201: Advanced Mitochondrial Biogenesis and PGC-
therapeutic · Pages share 4 hypotheses
Section 253: Advanced Optogenetics and Chemogenetics fo
therapeutic · Pages share 4 hypotheses
Show 10 more
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)